Document is current

Article History

Received: 20 September 2024

Accepted: 17 December 2024

First Online: 23 December 2024

Declarations

:

: The establishment and data collection of MoBa and the MS registry was based on a license from the Norwegian Data Protection Agency and approval from the Regional Committees for Medical and Health Research Ethics (REC). The MoBa cohort and the MS registry is regulated by the Norwegian Health Registry Act. Ethics approval for the current study was obtained from REC (reference 2016/906). Written informed consent was obtained from all participants during inclusion in MoBa and the MS Registry, for use of information in research and for data linkage to other registries and databases.

: Not applicable.

: KE has received honoraria from Novartis. ØT has received speaker honoraria from Teva, Novartis, Merck, Biogen, Sanofi, and Bristol Myers Squibb. JA reports no disclosures. MC has received speaker honoria from Roche. TH has received speaker honoraria from Roche, Novartis, Merck, Biogen, Sanofi and Bristol Myers Squibb. K-MM has served on scientific advisory board for Alexion, received speaker honoraria from Biogen, Novartis, Roche and Sanofi, and has participated in clinical trials organized by Biogen, Merck, Novartis, Otivio, Roche and Sanofi. TR reports no disclosures. SW has received speaker honoraria from Novartis, Biogen, and Sanofi. NEG has received speaker’s or consultative honoraria from UCB, Argenx, Johnson & Johnson, Roche, Merck, Alexion, Immunovant, Huma, Denka, Dianthus, Amgen, Grifols and Takeda. M-HB has received fees paid to her institution by valproate market authorization holders for EMA-mandated contract research, personal fees from Eisai, Novartis, Jazz Pharmaceuticals, Angelini Pharma, Teva, Lilly, and Lundbeck, and grants from the Research Council of Norway and NordForsk.